Course Notes & other materials

Home
Week 1: 28 Aug
Week 2: 04 Sept
Week 3: 11 Sept
Week 4: 18 Sept
Week 5: 25 Sept
Week 6: 02 Oct
Week 7: 09 Oct
Week 8: 16 Oct
Week 9: 23 Oct
Week 10: 30 Oct
Week 11: 06 Nov
Week 12: 13 Nov
Week 13: 20 Nov
Week 14: 27 Nov

News & information


Syllabus was updated 16 July 2018


16 August 2018: The CDC reports 107 cases of measles in the US in the first half of 2018; there were 117 cases in all of 2017. Almost all were in unvaccinated people, and thought to be acquired from contact with overseas travelers, or during travel.

20 July 2018: Venezuela has recoded 1842 cases of measles in an outbreak that's lasted over a year; by definition it is now endemic there (and in refugee populations across borders.) The Americas may lose the "measles-free" designation, under which the only cases are associated with foreign travel.

7 May 2018: The FDA has approved the start of a small Phase 2 trial for M-001, a possible universal flu vaccine. The vaccine consists of 3 repeats of 9 conserved linear epitopes that are prepared as a single recombinant protein. The M-001 vaccine is expected to protect against existing as well as future seasonal and pandemic virus strains.

23 March 2018: A trial of rovalpituzumab tesirine (a monoclonal antibody against the small-cell lung cancer tumor antigen DLL3 coupled to a toxic molecule) did not reach expected results for accelerated FDA approval in lung cancer. Other trials continue. AbbVie paid $5.8 billion for rights to the drug.

27 Sept. 2017: Chemokine in the news: The chemokine CCL11 (also called eotaxin-1) was found at increased levels in the brains of former football players with chronic traumatic encephalopathy, but not with Alzheimer disease.

10 Sept. 2017: Giant drug and vaccine maker Sanofi is discontinuing work on its Zika vaccine. Partly due to federal government budget cuts, and partly due to decline in concern about the Zika epidemic, which seems to burning out as the herd effect takes over.

12 July 2017: An advisory committee to the FDA today unanimously recommended approval of the Novartis product tisagenlecleucel, which is a first for a CAR-T, or chimeric antigen receptor T cell. Patients' T cells are isolated from their blood and engineered to express an antibody receptor. Approval is for use in refractory or relapsed B cell acute lymhphblastic leukemia. We'll discuss this in week 12.

After a while, News and Information items are archived.


Brief Bio of JJC. This is me:Picture of JJ Cohen

Why is this course on line where anyone can read it?

Instructor: J. John Cohen, MDCM, PhD

THIS COURSE SITE IS BEING REVISED AND UPDATED NOW.

The course will run on Tuesdays, 28 August to 27 November 2018, from 1-3 PM (1300-1500 h).

Students in a degree program are enrolled by that program; please email us to tell us you'll be joining the course (since we don't find out any other way until late in the process, and you could miss out on important information). Non-degree students (PRAs, for example) need JJ Cohen's permission and signature to register; please drop him an email. The forms for you to register are on line; click Prospective Students, then Apply and then the CU Anschutz Non-Degree Students button.

Auditors are welcome, also with permission; please let JJ know your interest before the course starts. Space is limited, so contact JJ early.

IMMU 7630 is a course in human-based immunology designed for graduate students, clinicians, and others who are not necessarily immunologists. It considers the broad sweep of immunology and its relationships to other disciplines, focusing on ideas and concepts more than details. Sufficient clinical examples are included to establish relevance, and widely-used immunologically-based methods are discussed. We practice clear communication by constructing and maintaining an online discussion group to which we all contribute. These course notes serve as our textbook. Scroll down for the schedule, and link via the left-hand navbar to that week's page. There you can download pdf files of each Unit, which corresponds to about an hour of class. Look at the files and decide if you want to print them. There is supplementary material on each week's page. This site is continuously revised and updated.
Crucial advice: Always read the notes before coming to class!

There's no required text. If you want to consider buying a text, click here for 2017 recommendations.
Essential to read: Syllabus, with rules, course organization, grading, schedule, and advice: You can download a hard copy.
Students requiring special accomodations: speak to JJC, and click here.
Information about UCD faculty and staff tuition waivers here.

2018 Course Schedule

(printable version)

Week
Date
Unit
Topic
1 28 Aug 1 Introduction to Course & Immunology
2 Innate to Adaptive Immunity
2 04 Sept 3 Anatomy & Physiology of the Immune System
    4 Antibody Structure
3 11 Sept 5 Antibody Genes
    6 Antibody Function
4 18 Sept 7 Monoclonal Antibodies and Antibody Techniques
    8 Ontogeny of the Immune System
5 25 Sept 9 T Cells
    10 T Cells
6 02 Oct 11 Immunogenetics & Transplantation
    12 Immunity & Vaccines
7 09 Oct 13 MIDTERM TEST
    14 MIDTERM TEST
8 16 Oct 15 Immunodeficiencies
    16 Immunology of AIDS
9 23 Oct 17 Immunopathology Type III: Immune Complex Disease
    18 Immunopathology Type II: Autoimmunity
10 30 Oct 19 Immunopathology Type I: Allergy & Parasite Immunity
    20 Immunopathology Type IV: T Cell Mediated
11 06 Nov 21 Chronic Frustrated Immune Responses & Regulation
    22 Immunohematology
12 13 Nov 23 Tumor Immunology
    24 Immunomodulators and Biological Response Modifiers
13 20 Nov 25 Lymphomas, New Developments & Ideas
    26 Overview & Review
14 27 Nov 27 FINAL TEST
    28 FINAL TEST